MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.

Slides:

Advertisements

Similar presentations

KRAS testing in colorectal cancer

Advertisements

Fluorescent In Situ Hybridization (FISH) to Identify Genetic Changes in Fine Needle Biopsy of Lung Lesions Prepared by Jin Jen NCI.

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Figure S1 a b c d DAPI Lgr β-catenin Merge

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

Rearrangements of Gene A and Gene B

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

(A) Timeline of the patient’s clinical events and interventions.

Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the specific MET antibody (Met (D1C2) XP Rabbit.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities.

Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

Expression of IL-1α in goblet cells and their destruction during DSS-induced colitis. Expression of IL-1α in goblet cells and their destruction during.

Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Predictive biomarker analyses in cytological specimens

Fluorescence-stained images and respective bright-field images of mouse spleen tissue sections area investigated using Raman spectroscopy. Fluorescence-stained.

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

A. glioblastoma with high (+++) KIT protein expression.

Volume 130, Issue 3, Pages (September 2013)

Volume 77, Issue 9, Pages (May 2010)

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Cardiac Fibrosis at 18 Weeks Post TAC (A) Representative images (original magnification ×20) of Picrosirius red-stained cardiac tissue sections from HF +

MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization Serena Varesano, PhD, Sandra Salvi, PhD, Simona Boccardo, PhD, Jean.

Axonal swelling and impairment of dendritic development in Purkinje cells from Pex14ΔC/ΔC BL/ICR mouse upon treatment with BDNF. Axonal swelling and impairment.

Gayatry Mohapatra, Rebecca A. Betensky, Ezra R

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Amplification of MET in a Patient with Malignant Pleural Mesothelioma

Identification and characterization of a novel KRAS rearrangement in metastatic prostate cancer. Identification and characterization of a novel KRAS rearrangement.

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

IHC detection of p-mTOR Ser 2448 in subcortical white matter during postnatal rat CNS development. IHC detection of p-mTOR Ser 2448 in subcortical white.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

FAK overexpression in invasive human breast cancer and DCIS

GC reaction is impaired in NOTCH2 knock-in mice.

FAK overexpression in invasive human colon cancer and colon dysplasia.

Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.

A, TSG-6 staining in TRAMP tissue and TRAMP cell lines.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

DNA damage-induced RPA foci in asynchronous cells labeled with BUdR.

SAF-1 expression in clinical breast cancer tissues.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Representative macrophage staining images only from the knee joints of CAIA mice injected s.c. with GalNAc–MASP-3–siRNA duplex 2 or GalNAc–luciferase–siRNA.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

CA-MSCs differentially secrete GM-CSF.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Detection of mutant alleles using ddPCR.

Frequent coamplification of RTKs in MET-amplified EGC

A and B, two blocks from the original specimen used for TMA demonstrated areas with varying patterns of ALK rearrangement and KRAS mutation status. A and.

Progastrin staining in colon adenomas and adenocarcinomas.

Defining the eTME genes.

a b c Supplementary Figure 1

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

EGF induces HPSE nucleolar localization in human BMBC cells.

Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

CD36 expression in tissue adjacent and distal to the tumor.

Recurrent tumor cell–intrinsic transcriptomic, RTKinomic, and immune regulomic alterations in regressing melanoma on MAPKi therapy. Recurrent tumor cell–intrinsic.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

HER2 amplification in EGFRT790M–negative tumors with acquired resistance. HER2 amplification in EGFRT790M–negative tumors with acquired resistance. A,HER2.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. FISH analysis showing amplification of the MET gene in formalin-fixed paraffin embedded (FFPE) tissue sections from 3 patients with colorectal cancer (#1, #2, and #3; A–C) who developed resistance to therapy with the anti-EGFR monoclonal antibodies panitumumab (Pmab) or cetuximab (Cmab). MET (7q31)–specific probe is labeled with Texas red, whereas chromosome 7 centromeric probe D7Z1 (7p11.1–q11.1) is marked in green. IHC staining for MET is shown in the left of each panel. FISH, original magnification ×60; IHC, original magnification ×40. Alberto Bardelli et al. Cancer Discovery 2013;3:658-673 ©2013 by American Association for Cancer Research